Kintor Pharmaceutical Limited
KNTPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -94.6% | – | – | 100% |
| R&D Expenses | $0 | $1 | $1 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$1 | $1 |
| Operating Expenses | $0 | $1 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -2,891.4% | – | – | -2,452.8% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$1 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -3,105.8% | – | – | -2,460% |
| EPS | -0.36 | -2.47 | -2.53 | -2.36 |
| % Growth | 85.4% | 2.4% | -7.2% | – |
| EPS Diluted | -0.36 | -2.47 | -2.53 | -2.36 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | -2,567.4% | – | – | -2,418.8% |